Theravance Biopharma to Be Acquired by Zymeworks for $17 Per Share Plus CVR

Theravance Biopharma completed a merger with Zymeworks, delivering $17.00 in cash per share plus one contingent value right (CVR) to shareholders and taking the company private. In connection with the deal, a CVR framework was established providing holders with a share of potential ampreloxetine mo…